Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

AIMS: Statins reduce cardiovascular risk in patients with acute coronary syndrome (ACS) and normal-to-moderately impaired renal function. It is not known whether proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors provide similar benefit across a range of renal function. We determined w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuñón, José, Steg, Philippe Gabriel, Bhatt, Deepak L, Bittner, Vera A, Díaz, Rafael, Goodman, Shaun G, Jukema, J Wouter, Kim, Yong-Un, Li, Qian H, Mueller, Christian, Parkhomenko, Alexander, Pordy, Robert, Sritara, Piyamitr, Szarek, Michael, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700757/
https://www.ncbi.nlm.nih.gov/pubmed/32820320
http://dx.doi.org/10.1093/eurheartj/ehaa498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700757/
https://www.ncbi.nlm.nih.gov/pubmed/32820320
http://dx.doi.org/10.1093/eurheartj/ehaa498

Ejemplares similares